Sai Parenteral's IPO
Open MainLineCurrent GMP
₹0 (0.00%)
Price Band
₹ 372 – 392
Lot Size
38
Issue Size
₹409 Cr
Minimum Investment
₹14896 (38 Shares)
Listing Date
02 April 2026
Subscription
1.05x
About the Company
Incorporated in 2001, Sai Parenteral’s Ltd. is a diversified pharmaceutical formulations company with strong capabilities in research, development, and manufacturing.
The company operates through two primary business segments:
- Branded Generic Formulations
- Contract Development and Manufacturing Organisation (CDMO) services for both domestic and international markets
Sai Parenteral’s offers a broad product portfolio across multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Its products are available in various dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.
The company serves a diverse customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists across India.
In FY 2023, Sai Parenteral’s expanded into international markets following the acquisition of two internationally accredited manufacturing facilities in Hyderabad, Telangana. It now exports to regulated and semi-regulated markets, including Australia, New Zealand, Southeast Asia, the Middle East, and Africa.
Sai Parenteral’s operates five manufacturing facilities in India. Four of these are located in Hyderabad, Telangana, including:
- A GMP-compliant injectable unit
- A WHO-GMP certified injectable unit
- A TGA (Australia) and PIC/S accredited solid oral dosage facility
- A WHO-GMP certified cephalosporin unit
Additionally, its wholly owned subsidiary, Revat Laboratories, operates a GMP-certified manufacturing facility in Ongole, Andhra Pradesh.
As of August 31, 2025, the company employed 277 full-time staff members.
Promoters
- Anil Kumar Karusala
- Vijitha Gorrepati
- Karusala Aruna
Promoters Holding
Holding Pre Issue
61.23%
Holding Post Issue
0.00%
Objects of the Issue
The Company Sai Parenteral's IPO proposes to utilise the Net Proceeds from the Issue towards the following objects.
- Capacity expansion and upgradation of manufacturing facilities
- Establishment of a new R&D centre
- Repayment / prepayment of certain outstanding borrowings
- Working capital requirements
- Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia)
- General corporate purposes
Address / Contact Info
Sai Parenteral's Ltd.
Plot No 39
5th floor, Lavanya Arcade Jayabheri Enclave
Gachibowli, K.V.Rangareddy, Seri Lingampally
Hyderabad, Telangana, 500032
Phone: +91 79979 91301
Email: cs@saiparenterals.com
Website: https://www.saiparenterals.com/
IPO Snapshot
IPO Timeline (Tentative)
IPO Open Date
Tuesday, 24 March 2026
IPO Close Date
Friday, 27 March 2026
Basis of Allotment
Monday, 30 March 2026
Initiation of Refunds
Wednesday, 01 April 2026
Credit of Shares to Demat
Wednesday, 01 April 2026
Listing Date
Thursday, 02 April 2026 — NSE & BSE
Important Dates
Open Date
24 March 2026
Close Date
27 March 2026
Basis Of Allotment
30 March 2026
Listing Date
02 April 2026
Financial Performance (₹ in Crores)
| Particular | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 376.24 | 272.39 | 268.1 | 133.96 |
| Revenue | 89.43 | 163.74 | 155.18 | 97.03 |
| Profit After Tax | 7.76 | 14.43 | 8.42 | 4.38 |
| Net Worth | 209.37 | 95.78 | 76.4 | 31.49 |
| Reserve & Surplus | 188.84 | 80.36 | 61.3 | 24.34 |
| Total Borrowings | 76.07 | 93.95 | 118.79 | 68.55 |
EPS Pre
5.43%
EPS Post
0.00%
P/E Pre
72.19
P/E (Post Issue)
0.00x
Company Financial Information
KPI Information (₹ in Crores)
| Particular | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| ROE % | 5.13 | 16.82 | 15.67 | 15.75 |
| ROCE % | 9.28 | 28.92 | 20.52 | 21.04 |
| Debt / Equity | 0 | 0 | 0 | 0 |
| RoNW % | 5.09 | 15.09 | 11.01 | 13.9 |
| PbW | 0 | 0 | 0 | 0 |
| Pat Margin % | 8.93 | 8.88 | 5.47 | 4.52 |
Return Ratio
IPO Reservations
| Category | Shares Offered | Shares Offered % | Max Allotee |
|---|---|---|---|
| Qualified Institutions | 2112900 | 28.09 | 0 |
| Non-Institutional | 1622876 | 21.57 | 0 |
| BNII | 1081918 | 14.38 | 0 |
| SNII | 540958 | 7.19 | 0 |
| Retail Investors | 3786710 | 50.34 | 0 |
| Total | 7522486 | 100 | 0 |
Subscription Status ( Fri, 27 Mar 26 01:50 PM)
| Category | Shares Offered | Shares Bid For | Subscription (x) |
|---|---|---|---|
| Qualified Institutions | 2112900 | 3610266 | 1.71x |
| Non-Institutional | 1622876 | 3831502 | 2.36x |
| BNII | 1081918 | 3707318 | 3.43x |
| SNII | 540958 | 124184 | 0.23x |
| Retail Investors | 3786710 | 439204 | 0.12x |
| Total | 7522486 | 7880972 | 1.05x |
Subscription figures are updated periodically and may change until issue closing. Data reflects bids placed across exchanges.
Peer Comparision
| Company | Face Value | PE Ratio | EPS Basic | EPS Diluted | RoNW | Net Assets |
|---|---|---|---|---|---|---|
| Sai Parenteral's Ltd | 5 | 0.00 | 5.43 | 5.43 | 15.09 | 35.98 |
| Sai Life Sciences Ltd | 1 | 107.70 | 8.83 | 8.61 | 7.99 | 102.12 |
| Innova Captab Ltd | 10 | 32.45 | 22.41 | 22.41 | 13.37 | 167.66 |
| Senores Pharmaceutic als Ltd | 10 | 64.30 | 16.12 | 16.12 | 7.18 | 176.37 |
| Gland Pharma Ltd | 1 | 44.71 | 42.40 | 42.40 | 7.63 | 555.41 |
Lot Size & Investment Details
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 38 | 14,896.00 |
| Retail (Max) | 13 | 494 | 193,648.00 |
| S-HNI (Min) | 14 | 532 | 208,544.00 |
| S-HNI (Max) | 67 | 2,546 | 998,032.00 |
| B-HNI (Min) | 68 | 2,584 | 1,012,928.00 |
Registrar
Bigshare Services Pvt Ltd
91-22-6263 8200
investor@bigshareonline.com
https://www.bigshareonline.com
Book Running Lead Managers
- Arihant Capital Markets Ltd
RHP Document
DRHP Document
Anchor Investors
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
Sai Parenteral's IPO is a Book-building IPO worth ₹409 crores. The price band is ₹372 to 392 per share. The IPO opens on Tue, Mar 24, 2026 and closes on Fri, Mar 27, 2026. It will be listed on BSE and NSE. Bigshare Services Pvt Ltd is the registrar.
The Sai Parenteral's IPO opens on Tue, Mar 24, 2026 and closes on Fri, Mar 27, 2026
Sai Parenteral's IPO Price Band is ₹372 to 392.
Sai Parenteral's IPO lot size is 38, and the minimum amount required for application is ₹14896.
The minimum investment for Sai Parenteral's IPO is approximately ₹14896 based on the upper price band.
To apply for the Sai Parenteral's IPO, investors can use the ASBA (Application Supported by Blocked Amount) process via their bank's net banking or apply through UPI using a registered broker or trading app. The IPO is available in retail, HNI, and institutional investor categories. Investors must select the lot size, enter bid details within the price band, and submit their application before the IPO closing date of Fri, Mar 27, 2026. After submission, funds are blocked until the basis of allotment of Sai Parenteral's IPO is finalised.
Sai Parenteral's IPO issue size is ₹409 crores.
Sai Parenteral's IPO allotment date is Sat, Jun 27, 2026.
The registrar for Sai Parenteral's IPO is Bigshare Services Pvt Ltd. Investors can go to Bigshare Services Pvt Ltd website for IPO allotment status, refund processing, and other queries related to Sai Parenteral's IPO through their official website or helpline.